Analyst Price Targets — INSM
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 12, 2026 10:16 am | — | Raymond James | $207.00 | $100.60 | StreetInsider | Insmed (INSM) PT Lowered to $207 at BofA Securities |
| September 30, 2026 9:23 am | — | Barclays | $207.00 | $115.63 | TheFly | Insmed price target lowered to $207 from $237 at Barclays |
| September 24, 2026 8:44 am | — | Goldman Sachs | $188.00 | $118.34 | TheFly | Insmed resumed with a Buy at Goldman Sachs |
| September 15, 2026 10:56 am | Adam Walsh | Roth Capital | $198.00 | $125.30 | TheFly | Insmed price target lowered to $198 from $212 at Roth Capital |
| August 10, 2026 2:31 pm | — | Truist Financial | $195.00 | $133.32 | TheFly | Insmed price target raised to $195 from $185 at Truist |
| August 7, 2026 1:40 pm | — | Morgan Stanley | $218.00 | $129.56 | TheFly | Insmed price target raised to $218 from $212 at Morgan Stanley |
| August 7, 2026 12:03 pm | — | Evercore ISI | $170.00 | $128.76 | TheFly | Insmed price target raised to $170 from $160 at Evercore ISI |
| August 7, 2026 11:39 am | — | Guggenheim | $205.00 | $132.55 | TheFly | Insmed price target lowered to $205 from $207 at Guggenheim |
| August 7, 2026 11:25 am | — | UBS | $172.00 | $132.55 | TheFly | Insmed price target raised to $172 from $166 at UBS |
| August 7, 2026 10:54 am | — | Wells Fargo | $169.00 | $132.55 | TheFly | Insmed price target raised to $169 from $161 at Wells Fargo |
Latest News for INSM
—Three Late-Breaking Abstracts at CHEST 2026 Deepen Understanding of the Potential of Treprostinil Palmitil Inhalation Powder (TPIP) Across Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)— —New Analysis From the Phase 3 ASPEN Study at CHEST 2026 Provides Additional Insights on Bronchiectasis Management— —Phase 3b ENCORE Study Findings at IDWeek 2026…
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Insmed shares slide after CFO Sara Bonstein's surprise exit, though the company reaffirms 2026 revenue guidance for Brinsupri and Arikayce.
Insmed Inc. (NASDAQ:INSM) shares are trading lower by almost 7% on Monday as traders digest a CFO transition update alongside a slightly softer risk tone.
— Sara Bonstein Will Step Down as CFO on October 30 After Nearly Seven Years of Dedicated Leadership — — Company Reaffirms Full-Year 2026 Financial Guidance — — Company Announces Third-Quarter 2026 Financial Results Conference Call to Be Held on Thursday, October 29, 2026 — BRIDGEWATER, N.J., Oct. 5, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for INSM.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.